U.S. markets closed

Syros Pharmaceuticals, Inc. (SYRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.2200-0.1000 (-2.31%)
At close: 4:00PM EDT
4.2400 +0.02 (+0.47%)
After hours: 07:51PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close4.3200
Bid4.1900 x 1200
Ask4.2300 x 1200
Day's Range4.1600 - 4.3200
52 Week Range4.0000 - 15.6500
Avg. Volume514,210
Market Cap261.348M
Beta (5Y Monthly)1.92
PE Ratio (TTM)N/A
EPS (TTM)-1.5780
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.14
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SYRS

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Syros Pharmaceuticals, Inc.
    Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • Business Wire

    Syros Reports Inducement Grant to Chief Financial Officer under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., October 13, 2021--Syros Pharmaceuticals (Nasdaq: SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the grant of an inducement stock option award to Jason Haas, the Company’s recently hired Chief Financial Officer, in accordance with Mr. Haas’s employment offer letter. The grant was approved by the Company’s Board of Directors and was made as a material inducement to Mr. Haas’s acceptance of employmen

  • Business Wire

    Syros Pharmaceuticals Announces Appointment of Jason Haas as Chief Financial Officer

    CAMBRIDGE, Mass., October 12, 2021--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Jason Haas as Chief Financial Officer. Mr. Haas brings more than 25 years of healthcare investment banking and corporate finance experience to Syros.

  • Insider Monkey

    Cathie Wood is Dumping These 15 Stocks

    In this article, we discuss the 15 stocks Cathie Wood is dumping. If you want to skip our detailed analysis of these stocks, go directly to Cathie Wood is Dumping These 5 Stocks. The portfolio value of ARK Investment Management, the New York-based hedge fund managed by Cathie Wood, has increased from over $50 billion […]